NCT05734482View on ClinicalTrials.gov

Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

July 3, 2023

Study Completion Date

July 3, 2023

Conditions

Psoriasis

Interventions

BIOLOGICAL

Secukinumab

for subcutaneous injection only

Trial Locations (1)

Unknown

The Second Hospital of Anhui Medical University, Hefei

All Listed Sponsors

lead

Taizhou Mabtech Pharmaceutical Co.,Ltd

INDUSTRY